Nearly all of patients with chronic myeloid leukemia (CML) and 20–30% of patients with acute lymphoblastic leukemia (ALL) have BCR–ABL1 gene fusions, which are the driving molecular abnormality of these diseases. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.